1. Home
  2. SGA vs RNTX Comparison

SGA vs RNTX Comparison

Compare SGA & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Saga Communications Inc. (FL)

SGA

Saga Communications Inc. (FL)

HOLD

Current Price

$8.98

Market Cap

56.6M

ML Signal

HOLD

Logo Rein Therapeutics Inc.

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.74

Market Cap

65.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGA
RNTX
Founded
1986
2001
Country
United States
United States
Employees
N/A
10
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.6M
65.7M
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
SGA
RNTX
Price
$8.98
$0.74
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
12.9K
385.3K
Earning Date
05-07-2026
05-15-2026
Dividend Yield
9.05%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$124,829,000.00
N/A
Revenue This Year
$6.74
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.65
N/A
52 Week Low
$8.24
$0.73
52 Week High
$13.51
$2.18

Technical Indicators

Market Signals
Indicator
SGA
RNTX
Relative Strength Index (RSI) 50.59 33.10
Support Level $8.26 N/A
Resistance Level $9.42 $1.32
Average True Range (ATR) 0.28 0.08
MACD 0.03 -0.01
Stochastic Oscillator 60.65 8.95

Price Performance

Historical Comparison
SGA
RNTX

About SGA Saga Communications Inc. (FL)

Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: